Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
|Deserunt mollit sunt Lorem laborum do id aliqua dolore||08 Feb 2022||Lorem|
|Pharming’s prophylactic HAE strategy considers different routes of admin, dosing after FDA CRL, sources say; experts see BioCryst’s Phase II/III BCX7353 as competitive threat||18 Jan 2019||Jennifer C. Smith-Parker|
|Pharming seeks Latin American partner by YE14 to file and commercialise HAE drug Ruconest - CEO||23 Apr 2014||Jinan Harb|
|Santarus/Pharming’s Ruconest for hereditary angioedema likely to be FDA-approved but market traction minimal||25 Jul 2012||Jennifer C. Smith-Parker|
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Insight on companies’ CRO and business development needs, strategies and relationships
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer